N
Nabil F. Saba
Researcher at Emory University
Publications - 386
Citations - 13122
Nabil F. Saba is an academic researcher from Emory University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 42, co-authored 310 publications receiving 9305 citations. Previous affiliations of Nabil F. Saba include University of Pittsburgh & American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more
TL;DR: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy.
Journal ArticleDOI
Sickle blood contains tissue factor–positive microparticles derived from endothelial cells and monocytes
Arun S. Shet,Omer Aras,Kalpna Gupta,Matthew J Hass,Douglas J. Rausch,Nabil F. Saba,Louann Koopmeiners,Nigel S. Key,Robert P. Hebbel +8 more
TL;DR: The concept that SCD is an inflammatory state with monocyte and endothelial activation and abnormal TF activity with elevated MPs derived from these cells is supported.
Journal ArticleDOI
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Mark Lynch,Vijayvel Jayaprakash,Li Li,Maura L. Gillison +20 more
TL;DR: Nivolumab significantly improved OS at the primary analysis and demonstrated prolonged OS benefit vs IC and maintenance of a manageable and consistent safety profile with 2-year follow-up.
Journal ArticleDOI
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml,Tanguy Y. Seiwert,David G. Pfister,Francis P. Worden,Stephen V. Liu,Jill Gilbert,Nabil F. Saba,Jared Weiss,Lori J. Wirth,Ammar Sukari,Hyunseok Kang,Michael K. Gibson,Erminia Massarelli,Steven M. Powell,Amy Meister,Xinxin Shu,Jonathan D. Cheng,Robert I. Haddad +17 more
TL;DR: Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status.
Journal ArticleDOI
An update on larynx cancer.
TL;DR: The care for patients with laryngeal cancer continues to evolve and truly requires a multidisciplinary team-based approach as discussed by the authors, which is the most common cause of lung cancer deaths.